A French Technology Transfer Office offers a new compound for the treatment of diabetes.

A French Technology Transfer Office (TTO) offers a new compound for the treatment of glucose intolerance and more precisely for the treatment of the diabetes thanks to the administration of a known molecule at a lower dosage. This new technology targets the market of drugs dealing with metabolic disorders.

The French TTO is looking for interested pharmaceutical corporations or biotechnology SMEs for a licensing agreement or for a technical cooperation agreement.

Type of partner sought: the partner sought could be a large corporate, medium-sized company or start-up operating in pharmaceutical, drug design or biotechnology development. More precisely, the TTO targets companies involved in the field of metabolic disorders interested in developing some more efficient therapeutic solutions for diabetes and obesity. A licensing agreement is open to pharmaceutical or biotech companies in case of further needed development to meet industrial and clinical challenges to commercialize drugs. A technical cooperation agreement is open to manufacturing drugs firms which are able to drive pre-clinical and clinical testing of the new compound.

Per maggiori informazioni clicca qui.

Sei interessato al profilo? Scrivi a een1@confindustria.lombardia.it